Search clinical trials for: MDG1011

Total 5 results

Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Medigene AG

Terminated

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Feasibility | Tolerability | Safety | Treatment Efficacy

Germany
Green Cross Corporation

Completed

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

Varicella (Chicken Pox)
Green Cross Corporation

Recruiting

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Varicella

Korea, Republic of
GC Biopharma Corp

Not yet recruiting

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Varicella Zoster Virus Infection

3

Subscribe